July 2022 - Page 3 of 4 - BioMedWire (BMW)

WednesdayJul 13, 2022 3:02 pm

Online Companies Offering Mental Health Services Come Under Spotlight

The need for therapists in the United States is currently at an all-time high, with the latest data from the CDC showing about 40% of adults in the country are struggling to find help for their substance abuse or mental health issues because of a therapist shortage. With no physical providers of the services they seek nearby, most are turning to online sources to meet their needs. Numerous digital mental health companies, such as BetterHelp, which offers access to therapy sessions, have been launched these last few years. These companies often receive backing from venture capital firms and provide a…

WednesdayJul 13, 2022 9:00 am

Homing Peptides: Silo Pharma Inc. (SILO) Targets ADRs

Silo’s partnership with UMB could yield therapeutics that limit side effects through precisely targeted delivery On February 3, 2022, Silo Pharma (OTCQB: SILO) extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and blood vessels). The ability to target inflamed tissue (while bypassing healthy organs) suggests joint-homing peptides could deliver therapeutics or fusion imaging nanoparticles to specific diseased tissues. Better imaging, lower radiation and precision, targeted dosing could enhance the therapeutic effect of current and future therapeutics and…

TuesdayJul 12, 2022 3:40 pm

Study Finds That Sex, Ethnicity May Impact Risk of Suicide After Concussion

Traumatic brain injuries are among the most difficult injuries to recover from. On top of causing issues such as speech difficulties and problems with logic, studies have found that individuals who sustain long-lasting symptoms from their injuries are more likely to develop mental health problems, including post-traumatic stress disorder (PTSD), depression and suicidal thoughts. Up to 30% of those who survive brain injuries go on to develop post-concussion syndrome, a condition that refers to long-term symptoms after a concussion. Common symptoms of post-concussive syndrome include headaches, brain fog, nausea, blurry vision and memory problems. An estimated 80% of concussion patients…

MondayJul 11, 2022 12:39 pm

New Study Finds Some Viruses Can Make You Tastier to Mosquitoes

Mosquitoes aren’t just loud and annoying, they take hundreds of thousands of lives per year by spreading diseases such as malaria, dengue fever, yellow fever and Zika. Researchers have now discovered a kind of cyclical relationship between mosquitoes and mosquito-borne viruses, including dengue fever and the Zika virus. The researchers found that once these viruses have infected humans and mice, they alter their scent and make them more attractive to mosquitoes. Attracted by your altered scent, the deadly bugs gorge on your infected blood and transport the viruses to their next victim. Once the new victim is infected, the cycle…

MondayJul 11, 2022 12:00 pm

Odyssey Health, Inc.’s (ODYY) Sports Advisory Board Enhancing Public Awareness and Understanding of Traumatic Brain Injuries

Odyssey’s Sports Advisory Board (“SAB”) was formed in 2021 to enhance public awareness of traumatic brain injuries and concussion The board’s members – Abby Wambach, Kurt Warner, and Brett Favre – have had storied careers in their respective sports and have expressed hope that scientists will examine their brains after their death to advance their understanding of head trauma Abby Wambach has committed her brain to research, hoping her efforts will bridge the gender gap in understanding sports concussions in women Sports concussions are worse for women, with female athletes being more likely to develop a sports-related concussion than their…

MondayJul 11, 2022 11:15 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Expands Patient Eligibility for Brain Cancer Drug Trial, Receives Approval from U.S. FDA for Protocol Amendment

Novel brain cancer drug developer CNS Pharmaceuticals, Inc. has received approval from the U.S. FDA for a Protocol Amendment that expands patient eligibility for participation in its potentially pivotal Phase 2 clinical trial for a novel drug candidate that targets the nearly 100 percent fatal cancer glioblastoma (“GBM”) CNS is developing the drug candidate Berubicin as an alternative to the standard-of-care chemotherapy agent, Lomustine, with the hope that Berubicin will prove itself at least as effective and potentially more so Berubicin has demonstrated the capacity to cross the blood-brain barrier in order to attack central nervous system tumors directly, which…

FridayJul 08, 2022 10:24 am

Researchers Believe Seasonal Allergies Are Worsening

Have you noticed that your pollen allergies are getting worse by the season? You’re not alone. Scientists from Columbia University Irving Medical Center have revealed that outdoor allergies have been getting worse. Physicians across the country say the past few allergy seasons have been more severe as historically high numbers of people sought treatment for allergy symptoms, including itchy eyes, sneezing and running noses. David A Gudis, an ear, nose and throat doctor at Columbia is certain that seasonal allergies are becoming more prevalent. He states that pollen allergies such as hay fever can have serious ramifications for some people…

ThursdayJul 07, 2022 12:13 pm

Study Suggests That Test of Memory May Signal Brain Tumor Presence

Diagnosing brain tumors in a timely manner can be difficult. Early symptoms of the deadly condition, such as coordination problems and persistent headaches, are common to several other medical conditions. Brain tumor diagnosis usually relies on magnetic resonance imaging (MRI) to spot the tumor and surgery or a biopsy to determine the kind of tumor. But the Brain Tumour Charity estimates that health professionals miss an overwhelming amount of brain cancer cases in their first investigation (99%) and that patients often go years before getting an accurate diagnosis. Researchers from the University of Edinburgh have developed a new verbal fluency…

WednesdayJul 06, 2022 1:58 pm

Brain Cell Regulation Mechanism Could Unlock Novel Treatment Modalities for Neurological Conditions

Neurological conditions such as Huntington's and Alzheimer’s disease as well as spinal cord injuries can be nigh impossible to treat. In most cases, all doctors and caregivers can do is reduce the severity of the symptoms and find ways to improve a patient’s quality of life. Consequently, scientists are always looking for more effective treatments for the millions of people in the world who live with neurological disorders. Researchers studying the brain and how it responds to disease and injury have now mapped a brain cell regulation mechanism that could allow them to develop novel treatments for brain disorders and…

WednesdayJul 06, 2022 11:15 am

Odyssey Health, Inc. (ODYY) Optimistic About Drug/Tech IP as Industry Studies Big Pharma M&A Outlook

Biopharma industry analysts have been expecting 2022 to be a heady year for big-pharma acquisitions or partnerships with promising medical upstarts following a time period that has left the biggest companies flush with cash Among promising device and drug developers, Odyssey Health Inc. has been working on novel solutions to brain concussion injuries, a rare neurodegenerative disease, obstructive choking incidents and early-stage coronary artery disease (“CAD”) detection Odyssey Health Inc. is taking its brain concussion solution to a Phase 1 clinical human trial currently with possible progression to Phase 2 before the end of the year The company likewise anticipates…